ProShare Advisors’s Blueprint Medicines BPMC Stock Holding History

ProShare Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,873	Closed	-$2.29M	–	2022
2025 Q2	$2.29M	Buy	17,873 +1,223	+7%	+$127K	﹤0.01%	672
2025 Q1	$1.47M	Sell	16,650 -4,265	-20%	-$416K	﹤0.01%	719
2024 Q4	$1.82M	Buy	20,915 +5,290	+34%	+$485K	﹤0.01%	721
2024 Q3	$1.45M	Buy	15,625 +3,613	+30%	+$359K	﹤0.01%	722
2024 Q2	$1.29M	Sell	12,012 -3,206	-21%	-$321K	﹤0.01%	719
2024 Q1	$1.44M	Buy	15,218 +1,268	+9%	+$109K	﹤0.01%	719
2023 Q4	$1.29M	Buy	13,950 +2,085	+18%	+$135K	﹤0.01%	708
2023 Q3	$596K	Buy	11,865 +44	+0.4%	+$2.35K	﹤0.01%	852
2023 Q2	$747K	Buy	11,821 +629	+6%	+$34.2K	﹤0.01%	796
2023 Q1	$504K	Sell	11,192 -2,352	-17%	-$106K	﹤0.01%	910
2022 Q4	$593K	Buy	13,544 +990	+8%	+$47.5K	﹤0.01%	884
2022 Q3	$828K	Buy	12,554 +224	+2%	+$14.4K	﹤0.01%	769
2022 Q2	$622K	Sell	12,330 -6,122	-33%	-$359K	﹤0.01%	872
2022 Q1	$1.18M	Sell	18,452 -4,089	-18%	-$294K	﹤0.01%	858
2021 Q4	$2.42M	Buy	22,541 +1,143	+5%	+$120K	﹤0.01%	722
2021 Q3	$2.2M	Sell	21,398 -6,374	-23%	-$594K	0.01%	696
2021 Q2	$2.44M	Buy	27,772 +3,883	+16%	+$356K	0.01%	679
2021 Q1	$2.32M	Buy	23,889 +2,028	+9%	+$202K	0.01%	662
2020 Q4	$2.45M	Buy	21,861 +5,216	+31%	+$550K	0.01%	585
2020 Q3	$1.54M	Sell	16,645 -263	-2%	-$20.3K	0.01%	627
2020 Q2	$1.32M	Buy	16,908 +6,125	+57%	+$414K	0.01%	636
2020 Q1	$631K	Sell	10,783 -7,654	-42%	-$493K	﹤0.01%	689
2019 Q4	$1.48M	Sell	18,437 -1,577	-8%	-$118K	0.01%	686
2019 Q3	$1.47M	Buy	20,014 +973	+5%	+$84.1K	0.01%	654
2019 Q2	$1.8M	Sell	19,041 -436	-2%	-$36K	0.01%	617
2019 Q1	$1.56M	Buy	19,477 +226	+1%	+$16.7K	0.01%	653
2018 Q4	$1.04M	Sell	19,251 -3,704	-16%	-$225K	0.01%	695
2018 Q3	$1.79M	Sell	22,955 -916	-4%	-$63.7K	0.01%	639
2018 Q2	$1.51M	Sell	23,871 -1,772	-7%	-$141K	0.01%	686
2018 Q1	$2.35M	Sell	25,643 -1,792	-7%	-$154K	0.02%	584
2017 Q4	$2.07M	Buy	27,435 +2,731	+11%	+$192K	0.01%	597
2017 Q3	$1.72M	Buy	24,704 +1,244	+5%	+$66.5K	0.02%	596
2017 Q2	$1.19M	Buy	23,460 +3,000	+15%	+$127K	0.01%	688
2017 Q1	$818K	Sell	20,460 -808	-4%	-$28.9K	0.01%	819
2016 Q4	$597K	Buy	21,268 +2,088	+11%	+$62.9K	0.01%	991
2016 Q3	$570K	Sell	19,180 -3,546	-16%	-$88.1K	0.01%	896
2016 Q2	$460K	Buy	22,726 +1,520	+7%	+$27.6K	0.01%	1012
2016 Q1	$383K	Sell	21,206 -1,951	-8%	-$33.9K	0.01%	1105
2015 Q4	$610K	Buy	+23,157	New	+$521K	0.01%	946

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ProShare Advisors's BPMC Position: Q3 2025 in Review

ProShare Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 17,873 shares — an estimated $2.29M sold.

ProShare Advisors first reported a position in BPMC in Q4 2015 and held it in 39 quarters. The position peaked at $2.45M in Q4 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

ProShare Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
ProShare Advisors sold 17,873 Blueprint Medicines shares in Q3 2025, an estimated $2.29M.
ProShare Advisors first reported a position in Blueprint Medicines in Q4 2015 and held it in 39 quarters.
ProShare Advisors's Blueprint Medicines position peaked at $2.45M in Q4 2020.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.